logo
logo
CLYM stock ticker logo

Climb Bio, Inc.

NASDAQ•CLYM
CEO: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-08-10
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Contact Information
PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE, 19808-1609, United States
866-857-2596
eliemtx.com
Market Cap
$499.79M
P/E (TTM)
-8.3
17.5
Dividend Yield
--
52W High
$8.03
52W Low
$1.05
52W Range
90%
Rank49Top 66.7%
3.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.26+0.00%
4-Quarter Trend

FCF

-$15.64M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Narrows Net loss narrowed to $(59.851M) USD in 2025 from $(73.897M) USD in 2024, showing operational improvement.
R&D Investment Surge Research and development expenses rose $32.377M to $46.713M USD, driven by advancement of budoprutug programs.
Strong Liquidity Position Cash and marketable securities totaled $160.744M USD as of December 31, 2025, funding operations into 2028.

Risk Factors

Future Capital Needs Expect continued operating losses; substantial future financing required to fund development and potential commercialization efforts.
Development Uncertainty Clinical development is lengthy, complex, and expensive; success is not guaranteed for product candidates like budoprutug.
Internal Control Weaknesses Material weaknesses in internal control over financial reporting remain unremediated as of December 31, 2025, impacting timely reporting.

Outlook

Budoprutug pMN Data Expected Anticipate reporting initial data from the low dose cohort of the PrisMN Phase 2 trial in the second half of 2026.
SC Formulation Data Coming Plan to share initial data from the Phase 1 clinical trial of the subcutaneous formulation in the first half of 2026.
CLYM116 Phase 1 Results Expect initial data from the CLYM116 Phase 1 trial in mid-2026 to support advancement into IgA Nephropathy patients.

Peer Comparison

Revenue (TTM)

AGEN stock ticker logoAGEN
$106.83M
-33.4%
SPRO stock ticker logoSPRO
$35.77M
-64.7%
SEER stock ticker logoSEER
$16.58M
+18.2%

Gross Margin (Latest Quarter)

SPRO stock ticker logoSPRO
100.0%
+0.0pp
OVID stock ticker logoOVID
87.1%
-12.9pp
SEER stock ticker logoSEER
52.0%
+4.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CLYM$499.79M-8.3-33.4%0.3%
CNTX$268.29M-10.5-30.9%0.2%
ABOS$203.53M-1.5-97.4%21.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Mar 24, 2026
|
EPS:-$0.20
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data